TAFI gene polymorphisms in patients with cerebral venous thrombosis

Tokgoz S., Zamani A. G., Durakbasi-Dursun H. G., Yilmaz O., Ilhan N., Demirel S., ...Daha Fazla

ACTA NEUROLOGICA BELGICA, cilt.113, sa.3, ss.291-297, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 113 Sayı: 3
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1007/s13760-012-0170-6
  • Dergi Adı: ACTA NEUROLOGICA BELGICA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.291-297
  • Anahtar Kelimeler: TAFI, Cerebral venous thrombosis, 438G > A, 505A > G, 1040C > T, Sinus thrombosis, ACTIVATABLE FIBRINOLYSIS INHIBITOR, ISCHEMIC-STROKE, MYOCARDIAL-INFARCTION, ANTIGEN LEVELS, INCREASED RISK, PLASMA-LEVELS, ASSOCIATION, DISEASE, THROMBOEMBOLISM, IDENTIFICATION
  • Akdeniz Üniversitesi Adresli: Hayır

Özet

Gene polymorphisms of thrombin activatable fibrinolysis inhibition (TAFI) factor have been investigated in various studies in terms of etiology (recurrence) and treatment (fibrinolytic effect) of thrombus formation. Cerebral venous thrombosis (CVT) is a life-threatening disease observed in young persons. Fifty-nine patients with CVT and 100 healthy control subjects were enrolled in the case/control study. The association between TAFI gene polymorphisms -438G > A, +505A > G and +1040C > T and cerebral venous thrombosis was investigated. It was found that frequencies of polymorphic genotype and allele were not different in patients than in control group and that they were not significant for cerebral venous thrombosis.